Why the study?
The clinical value of HDAC4 in patients with coronary heart disease was not established.
Does circulating HDAC4 level correlate with disease severity and predict MACE risk in patients with coronary heart disease?
Does circulating HDAC4 level correlate with disease severity and predict MACE risk in patients with coronary heart disease?
Circulating HDAC4 levels are reduced in CHD and correlate with coronary stenosis and inflammation, but do not significantly predict major adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
Lower HDAC4 may signal inflammation in CHD; hypothesis-generating for prognosis, needs validation before clinical use.
Aim: To investigate the clinical value of HDAC4 in coronary heart disease (CHD) patients. Methods: The serum HDAC4 levels were determined by ELISA in 180 CHD patients and 50 healthy controls. Results: HDAC4 was decreased in CHD patients compared with healthy controls (p < 0.001). HDAC4 was negatively linked with serum creatinine (p = 0.014), low-density lipoprotein cholesterol (p = 0.027) and C-reactive protein (p = 0.006) in CHD patients. Moreover, HDAC4 was inversely related to TNF-α (p = 0.012), IL-1β (p = 0.002), IL-6 (p = 0.034), IL-17A (p = 0.023), VCAM1 (p = 0.014) and Gensini score (p = 0.001). Unfortunately, neither HDAC4 high (vs low) (p = 0.080) nor HDAC4 quartile (p = 0.268) estimated major adverse cardiovascular event risk. Conclusion: Circulating HDAC4 levels have disease monitoring value but are less valuable in estimating prognosis in CHD patients.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: